Use Of Pi3k Inibitors For The Treatment Of Obesity

  • Published: Apr 25, 2012
  • Earliest Priority: Oct 21 2010
  • Family: 7
  • Cited Works: 61
  • Cited by: 2
  • Cites: 8
  • Additional Info: Cited Works Published

The full document isn't yet available to us from the patent office.


The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-± (Pgc1±) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.


Information currently unavailable.

Sign in to the Lens